Jean-Marc Classe1, Olivier Glehen2, Evelyne Decullier3, Jean Marc Bereder4, Simon Msika5, Gérard Lorimier6, Karine Abboud7, Pierre Meeus8, Gwenael Ferron9, François Quenet10, Frederic Marchal11, Sebastien Gouy12, Christophe Pomel13, Marc Pocard14, Frederic Guyon15, Naoual Bakrin16. 1. Institut de Cancérologie de l' Ouest, Centre René Gauducheau, Saint-Herblain, France jean-marc.classe@ico.unicancer.fr. 2. Université Lyon 1, EMR 3738, Villeurbanne, France Hôpital Lyon Sud, Pierre Bénite, Pierre-Bénite Cedex, France. 3. Hospices Civils de Lyon, Pôle IMER, Unité de méthodologie en recherche clinique, Lyon, France Université de Lyon, RECIF, EAM Santé Individu Société, Lyon, France Université Lyon 1, Lyon, France. 4. Centre Hospitalier L' Archet II, Nice, France. 5. Hopital Louis Mourier, Colombes, France. 6. Institut de Cancérologie de l' Ouest, Centre Paul Papin, Angers, France. 7. Hopital Nord, Saint-Priest-en-Jarez, France. 8. Centre Léon Bérard, Laennec, France. 9. IUCT Oncopole, Toulouse, France. 10. Centre Val d'Aurelle, Montpellier, France. 11. Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France. 12. Institut Gustave Roussy, Villejuif, France. 13. Centre Jean Perrin, Clermont-Ferrand, France. 14. Hopital Lariboisiere, Paris, France. 15. Institut Bergonie, Bordeaux, France. 16. Université Lyon 1, EMR 3738, Villeurbanne, France.
Abstract
BACKGROUND: To assess impact of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients treated for a first relapse of ovarian cancer (FROC). PATIENTS AND METHODS: Patients with a FROC treated with second-line chemotherapy, surgery and HIPEC were retrospectively included from 13 Institutions. Studied parameters were interval free between the end of initial treatment and the first relapse, second-line chemotherapy, peritoneal cancer index and completeness of surgery, HIPEC, mortality and morbidity, pathological results and survival. RESULTS: From 2001 to 2010, 314 patients were included. The main strategy was secondary chemotherapy followed by surgery and HIPEC (269/314-85.6%). Mortality and morbidity rates were respectively 1% and 30.9%. Median follow-up was 50 months, 5-year overall survival was 38.0%, with no difference between platinum-sensitive or -resistant patients and 5-year disease-free survival was 14%. CONCLUSION: HIPEC allows encouraging survival in the treatment of FROC, better in case of complete surgery, with acceptable mortality and morbidity rates. Copyright
BACKGROUND: To assess impact of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients treated for a first relapse of ovarian cancer (FROC). PATIENTS AND METHODS: Patients with a FROC treated with second-line chemotherapy, surgery and HIPEC were retrospectively included from 13 Institutions. Studied parameters were interval free between the end of initial treatment and the first relapse, second-line chemotherapy, peritoneal cancer index and completeness of surgery, HIPEC, mortality and morbidity, pathological results and survival. RESULTS: From 2001 to 2010, 314 patients were included. The main strategy was secondary chemotherapy followed by surgery and HIPEC (269/314-85.6%). Mortality and morbidity rates were respectively 1% and 30.9%. Median follow-up was 50 months, 5-year overall survival was 38.0%, with no difference between platinum-sensitive or -resistant patients and 5-year disease-free survival was 14%. CONCLUSION: HIPEC allows encouraging survival in the treatment of FROC, better in case of complete surgery, with acceptable mortality and morbidity rates. Copyright
Authors: Aurélie Derrien; Sébastien Gouard; Catherine Maurel; Marie-Hélène Gaugler; Frank Bruchertseifer; Alfred Morgenstern; Alain Faivre-Chauvet; Jean-Marc Classe; Michel Chérel Journal: Front Med (Lausanne) Date: 2015-12-21
Authors: Lisa Überrück; Giorgi Nadiradze; Can Yurttas; Alfred Königsrainer; Ingmar Königsrainer; Philipp Horvath Journal: Ann Surg Oncol Date: 2020-11-09 Impact factor: 5.344